{"protocolSection":{"identificationModule":{"nctId":"NCT06472479","orgStudyIdInfo":{"id":"LB2401-0001"},"organization":{"fullName":"The First Affiliated Hospital with Nanjing Medical University","class":"OTHER"},"briefTitle":"LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma","officialTitle":"A Clinical Study to Evaluate the Safety, Tolerance and Efficacy of LCAR-M61S and LCAR-M61D Cell Preparations in Patients With Relapsed/Refractory Multiple Myeloma"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-07-01","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2028-08-22","type":"ESTIMATED"},"completionDateStruct":{"date":"2029-10-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-06","studyFirstSubmitQcDate":"2024-06-24","studyFirstPostDateStruct":{"date":"2024-06-25","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-27","lastUpdatePostDateStruct":{"date":"2024-06-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Chen Lijuan","investigatorTitle":"Professor","investigatorAffiliation":"The First Affiliated Hospital with Nanjing Medical University"},"leadSponsor":{"name":"The First Affiliated Hospital with Nanjing Medical University","class":"OTHER"},"collaborators":[{"name":"Nanjing Legend Biotech Co.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"A prospective, two-cohort, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-M61S and LCAR-M61D in patients with relapsed/refractory multiple myeloma.","detailedDescription":"This study was a prospective, two-cohort, open-label clinical study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-M61S and LCAR-M61D in patients with relapsed/refractory multiple myeloma. All subjects who meet the eligibility criteria will receive intravenous injection of LCAR-M61S or LCAR-M61D cell injection. The study will include the following sequential phases: screening, apheresis, pre-treatment (lymphodepleting chemotherapy), treatment, and follow-up."},"conditionsModule":{"conditions":["Relapsed/Refractory Multiple Myeloma"],"keywords":["Multiple myeloma","Relapsed/Refractory multiple myeloma"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","interventionModelDescription":"Single Group Assignment \\& Two-cohort; LCAR-M61S and LCAR-M61D cells preparation intravenous infusion; Pretreatment of cyclophosphamide and fludarabine.","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":66,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"LCAR-M61S and LCAR-M61D","type":"EXPERIMENTAL","description":"Each subject will be given a single-dose LCAR-M61S or LCAR-M61D cells infusion at each dose level.","interventionNames":["Biological: LCAR-M61S cells preparation","Biological: LCAR-M61D cells preparation"]}],"interventions":[{"type":"BIOLOGICAL","name":"LCAR-M61S cells preparation","description":"Biological:\n\nLCAR-M61S or LCAR-M61D cells intravenous infusion; Prior to infusion of the LCAR-M61S and LCAR-M61D cell preparation, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.","armGroupLabels":["LCAR-M61S and LCAR-M61D"],"otherNames":["Cyclophosphamide","Fludarabine"]},{"type":"BIOLOGICAL","name":"LCAR-M61D cells preparation","description":"Biological:\n\nLCAR-M61S or LCAR-M61D cells intravenous infusion; Prior to infusion of the LCAR-M61S and LCAR-M61D cell preparation, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.","armGroupLabels":["LCAR-M61S and LCAR-M61D"],"otherNames":["Cyclophosphamide","Fludarabine"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Dose-limiting toxicity (DLT) rate","description":"DLT was classified according to the NCI-CTCAE V5.0 toxicity evaluation criteria and ASTCT consensus classification within 30 days after dose infusion (D1-D30), which was considered by the investigator or collaborator to be reasonably related to LCAR-M61S or LCAR-M61D cell therapy.","timeFrame":"From LCAR-M61S and LCAR-M61D cell preparations infusion (Day 1) until the 30th day of follow-up period, assessed up to 30 days"},{"measure":"Incidence, severity, and type of treatment-emergent adverse events (TEAEs)","description":"An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.","timeFrame":"From the date of signing ICF to the date (2 years after LCAR-M61S and LCAR-M61D cell preparation infusion (Day 1)"},{"measure":"To determine the recommended dose for phase II clinical trials (RP2D)","description":"RP2D established through accelerated titration design (ATD) and Bayesian Optimal Interval (BOIN) design","timeFrame":"Through the last subject of DLT exploration completion, about 2 years"},{"measure":"Maximum concentration (Cmax)","description":"The maximum observed concentration of CAR positive T cells or transgene CAR copy number in peripheral blood.","timeFrame":"From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years"},{"measure":"Time to Cmax (Tmax)","description":"The time it takes to reach the maximum concentration of CAR positive T cells or transgene CAR copy number in peripheral blood.","timeFrame":"From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years"},{"measure":"Time to the last observed concentration (Tlast)","description":"The time it takes to reach the last observed concentration of CAR positive T cells or transgene CAR copy number in peripheral blood.","timeFrame":"From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years"},{"measure":"Area Under the Curve (AUC) of the concentration","description":"The exposure of CAR positive T cells or transgene CAR copy number in peripheral blood experienced by the subject in a certain time interval.","timeFrame":"From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years"}],"secondaryOutcomes":[{"measure":"Objective Response Rate (ORR)","description":"According to International Myeloma Working Group (IMWG) efficacy criteria.ORR was defined as the proportion of patients with PR or better response after infusion of LCAR-M61S or LCAR-M61D cells.","timeFrame":"From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years"},{"measure":"Very Good Partial Response Rate（VGPR）","description":"Proportion of subjects achieving VGPR according to IMWG criteria.","timeFrame":"From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years"},{"measure":"Complete response（CR）","description":"Proportion of subjects achieving CR according to IMWG criteria.","timeFrame":"From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years"},{"measure":"Stringent complete response（sCR）","description":"Proportion of subjects achieving sCR according to IMWG criteria.","timeFrame":"From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years"},{"measure":"Minimal residual disease (MRD) negative rate","description":"Proportion of subjects achieving minimal residual disease (MRD) negative rate according to IMWG criteria.","timeFrame":"From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression，assessed about 2 years"},{"measure":"Time-to-response（TTR）","description":"According to International Myeloma Working Group (IMWG) efficacy criteria.TTR was defined as the interval from the date of the first infusion of the LCAR-M61S or LCAR-M61D cells preparation to the date of the first efficacy assessment for which the subject met all criteria for PR or better. Analyses were performed only in responders.","timeFrame":"From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years"},{"measure":"Duration of response（DOR）","description":"According to International Myeloma Working Group (IMWG) efficacy criteria. DOR was defined as the time from the first documented response (PR or better response) to the first documented evidence of disease progression (as defined according to IMWG criteria) or death from any cause .","timeFrame":"From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years"},{"measure":"Progression-free survival（PFS）","description":"According to International Myeloma Working Group (IMWG) efficacy criteria.PFS was defined as the interval from the date of the first infusion of the LCAR-M61S or LCAR-M61D cells preparation to the first documentation of disease progression (according to IMWG criteria) or death from any cause, whichever occurred first.","timeFrame":"From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years"},{"measure":"Overall survival（OS）","description":"According to International Myeloma Working Group (IMWG) efficacy criteria.Overall survival (OS) was defined as the interval from the date of the first infusion of LCAR-M61S or LCAR-M61D cells preparation to death.","timeFrame":"From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years"},{"measure":"Occurrence rate of antidrug antibody","description":"Occurrence rate of LCAR-M61S or LCAR-M61D cells preparation ADA","timeFrame":"From LCAR-M61S or LCAR-M61D cells preparation infusion until the date of first documented progression or study completion，assessed about 2 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects voluntarily participate in clinical research;\n* Age ≥18 years old;\n* Eastern Cooperative Oncology Group (ECOG) score 0-2;\n* Examination evidence of initial diagnosis of MM according to IMWG diagnostic criteria;\n* Measurable lesions were present;\n* Subjects have received at least three previous lines of multiple myeloma therapy, each with at least one complete therapy cycle, unless the best response to the therapeutic regimen was documented as disease progression (PD confirmed according to IMWG criteria);\n* Expected survival ≥3 months;\n* Clinical laboratory values in the screening period meet criteria;\n\nExclusion Criteria:\n\n* Received previous therapy targeting GPRC5D and/or CD19 targets;\n* Prior antineoplastic therapy and meet exclusion criteria (before apheresis);\n* Subjects had Waldenstrom macroglobulinemia, POEMS syndrome, or primary AL amyloidosis at the time of screening.\n* Subjects who were positive for any of HBsAg, HBV DNA, HCV-Ab, HCV RNA, and HIV-Ab;\n* Life-threatening allergic reactions, hypersensitivity reactions, or intolerance to CAR-T cell formulations or their excipients, including DMSO, are known.\n* Serious underlying diseases were present;\n* Female subjects who were pregnant, breastfeeding, or planning to become pregnant while participating in this study or within 1 year of receiving study treatment.\n* Also enrolled in other clinical studies.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Lijuan Chen","role":"CONTACT","phone":"15850521836","email":"chenljb@126.com"},{"name":"Xuxing Shen","role":"CONTACT","phone":"15720803161","email":"ruxiaoguo1992@163.com"}],"overallOfficials":[{"name":"Lijuan Chen","affiliation":"The First Affiliated Hospital with Nanjing Medical University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Anhui Cancer Hospital","city":"Hefei","state":"Anhui","zip":"230031","country":"China","contacts":[{"name":"Kaiyang Ding","role":"CONTACT","phone":"13966672170","email":"dingky@126.com"}],"geoPoint":{"lat":31.86389,"lon":117.28083}},{"facility":"Henan Cancer Hospital","city":"Zhengzhou","state":"Henan","zip":"450003","country":"China","contacts":[{"name":"Xudong Wei","role":"CONTACT","phone":"13837169301","email":"weixudong63@126.com"}],"geoPoint":{"lat":34.75778,"lon":113.64861}},{"facility":"Jiangsu Province Hospital","city":"Nanjing","state":"Jiangsu","zip":"210029","country":"China","contacts":[{"name":"Lijuan Chen","role":"CONTACT","phone":"15850521836","email":"chenljb@126.com"}],"geoPoint":{"lat":32.06167,"lon":118.77778}},{"facility":"Beijing Gobroad Hospital","city":"Beijing","zip":"102206","country":"China","contacts":[{"name":"Kai Hu","role":"CONTACT","phone":"15010390336","email":"huk@gobroadhealthcare.com"}],"geoPoint":{"lat":39.9075,"lon":116.39723}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000009101","term":"Multiple Myeloma"},{"id":"D000054219","term":"Neoplasms, Plasma Cell"}],"ancestors":[{"id":"D000009370","term":"Neoplasms by Histologic Type"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000020141","term":"Hemostatic Disorders"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010265","term":"Paraproteinemias"},{"id":"D000001796","term":"Blood Protein Disorders"},{"id":"D000006402","term":"Hematologic Diseases"},{"id":"D000006474","term":"Hemorrhagic Disorders"},{"id":"D000008232","term":"Lymphoproliferative Disorders"},{"id":"D000007160","term":"Immunoproliferative Disorders"},{"id":"D000007154","term":"Immune System Diseases"}],"browseLeaves":[{"id":"M12058","name":"Multiple Myeloma","asFound":"Multiple Myeloma","relevance":"HIGH"},{"id":"M27588","name":"Neoplasms, Plasma Cell","asFound":"Multiple Myeloma","relevance":"HIGH"},{"id":"M12315","name":"Neoplasms by Histologic Type","relevance":"LOW"},{"id":"M21977","name":"Hemostatic Disorders","relevance":"LOW"},{"id":"M5059","name":"Blood Coagulation Disorders","relevance":"LOW"},{"id":"M17400","name":"Vascular Diseases","relevance":"LOW"},{"id":"M13178","name":"Paraproteinemias","relevance":"LOW"},{"id":"M5077","name":"Blood Protein Disorders","relevance":"LOW"},{"id":"M9490","name":"Hematologic Diseases","relevance":"LOW"},{"id":"M9560","name":"Hemorrhagic Disorders","relevance":"LOW"},{"id":"M11225","name":"Lymphoproliferative Disorders","relevance":"LOW"},{"id":"M10206","name":"Immunoproliferative Disorders","relevance":"LOW"},{"id":"M10200","name":"Immune System Diseases","relevance":"LOW"},{"id":"T3947","name":"Multiple Myeloma","asFound":"Multiple Myeloma","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"BC15","name":"Blood and Lymph Conditions"},{"abbrev":"BC20","name":"Immune System Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000014740","term":"Vidarabine"},{"id":"D000003520","term":"Cyclophosphamide"},{"id":"C000024352","term":"Fludarabine"},{"id":"C000042382","term":"Fludarabine phosphate"}],"ancestors":[{"id":"D000007166","term":"Immunosuppressive Agents"},{"id":"D000007155","term":"Immunologic Factors"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000018501","term":"Antirheumatic Agents"},{"id":"D000018906","term":"Antineoplastic Agents, Alkylating"},{"id":"D000000477","term":"Alkylating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000970","term":"Antineoplastic Agents"},{"id":"D000019653","term":"Myeloablative Agonists"},{"id":"D000000964","term":"Antimetabolites, Antineoplastic"},{"id":"D000000963","term":"Antimetabolites"},{"id":"D000000998","term":"Antiviral Agents"},{"id":"D000000890","term":"Anti-Infective Agents"}],"browseLeaves":[{"id":"M6727","name":"Cyclophosphamide","asFound":"Cycle","relevance":"HIGH"},{"id":"M283230","name":"Fludarabine","asFound":"Comparison","relevance":"HIGH"},{"id":"M225513","name":"Fludarabine phosphate","asFound":"Comparison","relevance":"HIGH"},{"id":"M17485","name":"Vidarabine","asFound":"Comparison","relevance":"HIGH"},{"id":"M10212","name":"Immunosuppressive Agents","relevance":"LOW"},{"id":"M10201","name":"Immunologic Factors","relevance":"LOW"},{"id":"M20604","name":"Antirheumatic Agents","relevance":"LOW"},{"id":"M20942","name":"Antineoplastic Agents, Alkylating","relevance":"LOW"},{"id":"M3820","name":"Alkylating Agents","relevance":"LOW"},{"id":"M4281","name":"Antimetabolites","relevance":"LOW"},{"id":"M4314","name":"Antiviral Agents","relevance":"LOW"},{"id":"M4214","name":"Anti-Infective Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"ANeo","name":"Antineoplastic Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Infe","name":"Anti-Infective Agents"}]}},"hasResults":false}